TY - JOUR
T1 - Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy
T2 - A population-based cohort study
AU - Chen, Yung Tai
AU - Kuo, Shu Chen
AU - Chao, Pei Wen
AU - Chang, Yea Yuan
N1 - Publisher Copyright:
© 2019 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objectives Animal and ex vitro studies suggested lipid-lowering agents (LLAs) may be used as an adjunct to standard anti- tuberculosis (TB) treatment. No human study has been conducted to date. Using the Taiwan National Health Insurance Research Database (NHIRD), the current population-based cohort study sought to examine the association between use of LLAs and outcomes of patients with pulmonary TB receiving anti-TB treatment. Methods Using a NHIRD from 2003 to 2010, this population-based cohort study retrospectively examined the association between LLAs (statins or fibrates) and the outcomes of patients with pulmonary TB receiving anti-TB treatment. Results A total of 1452 adult patients newly diagnosed with pulmonary TB during the study period were identified and compared with 5808 matched patients. In the LAA cohort, 1258 received statin, and 295 received fibrate. Compared with patients who did not take LLA, patients who took oral LLAs had similar incidence of treatment completion at 9, 12, and 24 months. Conclusions Neither statins nor fibrates provide clinical benefit superior to that achieved with standard anti-tuberculosis treatment. Future clinical trials should investigate the effects of statins and fibrates on short-course standard anti-TB therapy.
AB - Objectives Animal and ex vitro studies suggested lipid-lowering agents (LLAs) may be used as an adjunct to standard anti- tuberculosis (TB) treatment. No human study has been conducted to date. Using the Taiwan National Health Insurance Research Database (NHIRD), the current population-based cohort study sought to examine the association between use of LLAs and outcomes of patients with pulmonary TB receiving anti-TB treatment. Methods Using a NHIRD from 2003 to 2010, this population-based cohort study retrospectively examined the association between LLAs (statins or fibrates) and the outcomes of patients with pulmonary TB receiving anti-TB treatment. Results A total of 1452 adult patients newly diagnosed with pulmonary TB during the study period were identified and compared with 5808 matched patients. In the LAA cohort, 1258 received statin, and 295 received fibrate. Compared with patients who did not take LLA, patients who took oral LLAs had similar incidence of treatment completion at 9, 12, and 24 months. Conclusions Neither statins nor fibrates provide clinical benefit superior to that achieved with standard anti-tuberculosis treatment. Future clinical trials should investigate the effects of statins and fibrates on short-course standard anti-TB therapy.
UR - http://www.scopus.com/inward/record.url?scp=85059866184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059866184&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0210479
DO - 10.1371/journal.pone.0210479
M3 - Article
C2 - 30633771
AN - SCOPUS:85059866184
SN - 1932-6203
VL - 14
JO - PLoS One
JF - PLoS One
IS - 1
M1 - e0210479
ER -
